Ovid Therapeutics  logo
Ovid Therapeutics OVID
$ 2.48 -5.53%

Annual report 2025
added 03-18-2026

report update icon

Ovid Therapeutics Income Statement 2011-2026 | OVID

Annual Income Statement Ovid Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

299 M 163 M 221 M 142 M 186 M 167 M 135 M 78.6 M 161 M - - - - - -

Shares

130 M 71 M 70.6 M 70.4 M 67.5 M 59.4 M 39.2 M 24.6 M 19.3 M - - - - - -

Historical Prices

2.3 2.3 3.13 2.01 2.76 2.81 3.6 2.83 8.5 - - - - - -

Net Income

-17.4 M -26.4 M -52.3 M -54.2 M 123 M -81 M -60.5 M -52 M -64.8 M -22.4 M -13.2 M - - - -

Revenue

7.25 M 566 K 392 K 1.5 M 208 M 12.6 M - - - - - - - - -

Gross Profit

- - - - - 12.6 K - - - - - - - - -

Operating Income

-42.4 M -61.9 M -59.3 M -55.5 M 124 M -81.4 M -61.4 M -52.9 M -65 M -22.5 M -13.2 M - - - -

Interest Expense

25 M 35.5 M 6.94 M 1.38 M -45.7 K - - - - - - - - - -

EBITDA

-42.2 M -61.3 M -58.7 M -55 M 124 M -81.1 M -61.2 M -52.8 M -64.9 M -22.5 M -13.2 M - - - -

Operating Expenses

49.7 M 62.5 M 59.7 M 57.1 M 84.2 M 94 M 61.4 M 52.9 M 65 M - - - - - -

General and Administrative Expenses

24.1 M 25.7 M 31.1 M 32.4 M 37.2 M 30.6 M 19.3 M 19.1 M 15 M 13 M 6.58 M - - - -

All numbers in USD currency

Quarterly Income Statement Ovid Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

71.2 M 71.1 M 71.1 M 71 M 71 M 70.9 M 70.7 M 70.7 M 70.6 M 70.5 M 70.5 M 70.5 M 70.4 M 70.4 M 70.3 M 70.4 M 67.9 M 67.8 M 66.1 M 65.7 M 59.4 M 55.6 M 54.7 M 54.7 M 54.7 M 54.7 M 54.7 M 24.7 M 24.6 M 24.6 M 24.6 M 24.6 M 24.6 M 18.1 M 9.84 M 9.84 M 9.84 M 9.84 M 9.84 M - - - - - - - - - - - - - - - - - - - -

Net Income

-12.2 M -4.68 M -10.2 M - -14 M 8.52 M -11.7 M - -11.3 M -12.4 M -13.4 M - -12 M -14.6 M -16.1 M - -11.4 M -15.8 M 176 M - -16.4 M -22.6 M -20 M -17 M -16.6 M -13.1 M -13.8 M -12.9 M -13 M -12.9 M -13.2 M -11 M -9.36 M -10.2 M -34.2 M -7.56 M -5.78 M -5.39 M -3.68 M - - - - - - - - - - - - - - - - - - - -

Revenue

132 K 6.27 M 130 K - 173 K 169 K 148 K - 109 K 75 K 66 K - 11.1 K - 1.45 M - - - 208 M - 6.91 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-12.5 M -5.07 M -12.6 M - -13.2 M -20.5 M -17.4 M - -12 M -14.2 M -14.9 M - -12.8 M -14.3 M -16.3 M - -11.7 M -14.3 M 177 M - -16.4 M -23.1 M -20.3 M - -16.8 M -13.3 M -14.1 M - -13.2 M -13.2 M -13.4 M - -9.41 M -10.3 M -34.3 M - -5.81 M -5.42 M - - - - - - - - - - - - - - - - - - - - -

Interest Expense

365 K 389 K 2.32 M - -780 K 29 M 5.72 M - 776 K 1.76 M 1.54 M - 836 K -284 K 209 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-12.5 M -5.01 M -12.4 M - -13.1 M -20.4 M -17.3 M - -11.9 M -14.1 M -14.7 M - -12.7 M -14.2 M -16.2 M - -11.5 M -14.2 M 177 M - -16.2 M -23 M -20.2 M - -16.6 M -13.2 M -14 M - -13.1 M -13.2 M -13.4 M - -9.35 M -10.3 M -34.2 M - -5.79 M -5.4 M 5.9 K - - - - - - - - - - - - - - - - - - - -

Operating Expenses

12.7 M 11.3 M 12.7 M - 13.4 M 20.7 M 17.6 M - 12.1 M 14.2 M 15 M - 12.8 M 14.3 M 17.7 M - 11.7 M 14.3 M 31.8 M - 23.3 M 23.1 M 20.3 M 17.3 M 16.8 M 13.3 M 14.1 M 13.1 M 13.2 M 13.2 M 13.4 M 11 M 9.41 M 10.3 M 34.3 M 7.59 M 5.82 M 5.42 M 3.71 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

6.78 M 4.88 M 6.02 M - 5.54 M 8.1 M 7.17 M - 6.8 M 8.25 M 8.34 M - 7.63 M 8.26 M 9.88 M - 6.76 M 6.63 M 15.6 M - 7.44 M 7.11 M 5.67 M - 5.17 M 4.2 M 4.72 M - 4.63 M 5.09 M 4.96 M - 3.51 M 4.21 M 2.98 M - 3.12 M 3.65 M 2.59 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Ovid Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Altimmune Altimmune
ALT
$ 3.45 3.29 % $ 304 M usaUSA
Amgen Amgen
AMGN
$ 351.92 1.18 % $ 189 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.55 0.26 % $ 914 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.4 1.82 % $ 357 M britainBritain
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 218.41 -1.57 % $ 5 B danmarkDanmark
Aytu BioScience Aytu BioScience
AYTU
$ 2.61 - $ 16.4 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 11.01 0.27 % $ 453 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.08 -0.48 % $ 194 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.59 4.28 % $ 186 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.6 -1.9 % $ 6.87 M israelIsrael
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.37 0.75 % $ 116 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cullinan Management Cullinan Management
CGEM
$ 12.91 1.33 % $ 778 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CorMedix CorMedix
CRMD
$ 6.32 1.12 % $ 455 K usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.96 3.92 % $ 3.45 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.26 0.35 % $ 707 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA